Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Iñigo Landa, … , Ian Ganly, James A. Fagin
Iñigo Landa, … , Ian Ganly, James A. Fagin
Published February 15, 2016
Citation Information: J Clin Invest. 2016;126(3):1052-1066. https://doi.org/10.1172/JCI85271.
View: Text | PDF
Clinical Research and Public Health Oncology

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

Abstract

BACKGROUND. Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) are rare and frequently lethal tumors that so far have not been subjected to comprehensive genetic characterization.

METHODS. We performed next-generation sequencing of 341 cancer genes from 117 patient-derived PDTCs and ATCs and analyzed the transcriptome of a representative subset of 37 tumors. Results were analyzed in the context of The Cancer Genome Atlas study (TCGA study) of papillary thyroid cancers (PTC).

RESULTS. Compared to PDTCs, ATCs had a greater mutation burden, including a higher frequency of mutations in TP53, TERT promoter, PI3K/AKT/mTOR pathway effectors, SWI/SNF subunits, and histone methyltransferases. BRAF and RAS were the predominant drivers and dictated distinct tropism for nodal versus distant metastases in PDTC. RAS and BRAF sharply distinguished between PDTCs defined by the Turin (PDTC-Turin) versus MSKCC (PDTC-MSK) criteria, respectively. Mutations of EIF1AX, a component of the translational preinitiation complex, were markedly enriched in PDTCs and ATCs and had a striking pattern of co-occurrence with RAS mutations. While TERT promoter mutations were rare and subclonal in PTCs, they were clonal and highly prevalent in advanced cancers. Application of the TCGA-derived BRAF-RAS score (a measure of MAPK transcriptional output) revealed a preserved relationship with BRAF/RAS mutation in PDTCs, whereas ATCs were BRAF-like irrespective of driver mutation.

CONCLUSIONS. These data support a model of tumorigenesis whereby PDTCs and ATCs arise from well-differentiated tumors through the accumulation of key additional genetic abnormalities, many of which have prognostic and possible therapeutic relevance. The widespread genomic disruptions in ATC compared with PDTC underscore their greater virulence and higher mortality.

FUNDING. This work was supported in part by NIH grants CA50706, CA72597, P50-CA72012, P30-CA008748, and 5T32-CA160001; the Lefkovsky Family Foundation; the Society of Memorial Sloan Kettering; the Byrne fund; and Cycle for Survival.

Authors

Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A. Knauf, Ronak H. Shah, Snjezana Dogan, Julio C. Ricarte-Filho, Gnana P. Krishnamoorthy, Bin Xu, Nikolaus Schultz, Michael F. Berger, Chris Sander, Barry S. Taylor, Ronald Ghossein, Ian Ganly, James A. Fagin

×

Figure 2

EIF1AX mutations and EIF1AX-RAS co-occurrence in thyroid cancers.

Options: View larger image (or click on image) Download as PowerPoint
EIF1AX mutations and EIF1AX-RAS co-occurrence in thyroid cancers. (A) D...
(A) Distribution of EIF1AX mutations in thyroid cancers and other tumors (modified from ref. 1). (B) Oncoprints showing the co-occurrence of EIF1AX with RAS mutations in PTC from TCGA (top, n = 401), PDTCs from our study (middle, n = 84), and ATCs from our series and from (21) (bottom, n = 55). (C) Kaplan-Meier graph showing significantly shorter survival in EIF1AX-mutated PDTCs (log-rank P = 0.048). See Supplemental Table 6 for detailed clinical correlations.